Free Trial
The Market Does Not Wait. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion

Cytokinetics (CYTK) Financials

Cytokinetics logo
$77.58 -0.48 (-0.61%)
As of 10:36 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Cytokinetics

Annual Income Statements for Cytokinetics

This table shows Cytokinetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -38 16 -128 -106 -122 -127 -215 -389 -526 -590 -785
Consolidated Net Income / (Loss)		 -38 16 -128 -106 -122 -127 -215 -389 -526 -590 -785
Net Income / (Loss) Continuing Operations		 -38 16 -128 -106 -122 -127 -215 -389 -526 -590 -785
Total Pre-Tax Income 		-38 16 -128 -106 -122 -133 -216 -400 -554 -641 -833
Total Operating Income		 -37 19 -113 -89 -99 -94 -186 -324 -496 -536 -612
Total Gross Profit		 29 106 13 32 27 56 70 95 7.53 18 88
Total Revenue		 29 106 13 32 27 56 70 95 7.53 18 88
Operating Revenue		 - - 13 32 27 56 70 95 7.53 18 88
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 66 88 127 120 126 150 257 419 504 555 700
Selling, General & Admin Expense		 20 28 36 31 40 53 97 178 174 215 284
Research & Development Expense		 46 60 90 89 86 97 160 241 330 339 416
Total Other Income / (Expense), net		 -0.09 -2.23 -14 -17 -23 -39 -29 -76 -58 -105 -221
Interest Expense		 0.27 2.70 17 22 27 39 29 51 58 87 225
Other Income / (Expense), net		 0.17 0.46 2.60 4.35 4.54 0.00 0.00 -25 0.00 -18 4.00
Other Gains / (Losses), net		 - - - - - 5.33 0.33 11 28 52 48
Basic Earnings per Share		 ($0.97) $0.41 ($2.59) ($1.95) ($2.11) ($1.97) ($2.80) ($4.33) ($5.45) ($5.26) ($6.54)
Weighted Average Basic Shares Outstanding		 38.81M 39.94M 49.40M 54.42M 57.58M 64.52M 76.89M 89.83M 96.52M 111.98M 120.10M
Diluted Earnings per Share		 ($0.97) $0.39 ($2.59) ($1.95) ($2.11) ($1.97) ($2.80) ($4.33) ($5.45) ($5.26) ($6.54)
Weighted Average Diluted Shares Outstanding		 38.81M 42.56M 49.40M 54.42M 57.58M 64.52M 76.89M 89.83M 96.52M 111.98M 120.10M
Weighted Average Basic & Diluted Shares Outstanding		 38.70M 41.73M 49.40M 54.42M 57.58M 64.52M 76.89M 95.16M 103.00M 118.41M 123.16M

Quarterly Income Statements for Cytokinetics

This table shows Cytokinetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -129 -138 -136 -143 -161 -150 -161 -134 -306 -183 -206
Consolidated Net Income / (Loss)		 -129 -137 -136 -143 -161 -150 -161 -134 -306 -183 -206
Net Income / (Loss) Continuing Operations		 -129 -137 -136 -143 -161 -150 -161 -134 -306 -183 -206
Total Pre-Tax Income 		-129 -158 -144 -155 -178 -176 -175 -147 -316 -195 -217
Total Operating Income		 -122 -127 -126 -130 -141 -139 -156 -112 -167 -178 -184
Total Gross Profit		 0.38 1.67 0.84 0.00 0.46 17 0.00 67 1.94 18 17
Total Revenue		 0.38 1.67 0.84 0.00 0.46 17 1.58 67 1.94 18 19
Operating Revenue		 0.38 1.67 0.84 0.00 0.46 17 1.58 67 1.94 18 19
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 1.58 0.00 0.00 - 2.55
Operating Cost of Revenue		 - - - - - - 1.58 - - - 2.55
Total Operating Expenses		 123 129 127 130 141 156 156 178 169 196 200
Selling, General & Admin Expense		 40 44 46 51 57 62 57 66 69 92 105
Research & Development Expense		 83 85 82 80 85 94 98 113 99 104 96
Total Other Income / (Expense), net		 -7.16 -31 -17 -25 -37 -37 -19 -36 -150 -16 -33
Interest Expense		 14 17 17 24 22 23 23 24 148 30 33
Other Income / (Expense), net		 6.84 -14 0.00 -0.40 -15 -15 3.50 -12 -2.10 14 -0.10
Other Gains / (Losses), net		 - - 7.91 12 17 - 14 13 10 11 11
Basic Earnings per Share		 ($1.35) ($1.38) ($1.33) ($1.31) ($1.36) ($1.26) ($1.36) ($1.12) ($2.55) ($1.51) ($1.67)
Weighted Average Basic Shares Outstanding		 96.07M 96.52M 101.92M 109.24M 117.69M 111.98M 118.50M 119.46M 119.98M 120.10M 123.27M
Diluted Earnings per Share		 ($1.35) ($1.38) ($1.33) ($1.31) ($1.36) ($1.26) ($1.36) ($1.12) ($2.55) ($1.51) ($1.67)
Weighted Average Diluted Shares Outstanding		 96.07M 96.52M 101.92M 109.24M 117.69M 111.98M 118.50M 119.46M 119.98M 120.10M 123.27M
Weighted Average Basic & Diluted Shares Outstanding		 98.05M 103.00M 104.85M 117.66M 118.01M 118.41M 119.43M 119.66M 122.26M 123.16M 124.43M

Annual Cash Flow Statements for Cytokinetics

This table details how cash moves in and out of Cytokinetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 45 1.80 58 -83 -5.82 47 30 -45 46 -18 30
Net Cash From Operating Activities		 4.88 37 -102 -101 -91 8.94 -143 -300 -414 -396 -510
Net Cash From Continuing Operating Activities		 4.88 37 -102 -101 -91 8.94 -143 -300 -414 -396 -510
Net Income / (Loss) Continuing Operations		 -38 16 -128 -106 -122 -127 -215 -389 -526 -590 -785
Consolidated Net Income / (Loss)		 -38 16 -128 -106 -122 -127 -215 -389 -526 -590 -785
Depreciation Expense		 0.59 0.74 1.92 1.24 1.29 1.83 2.28 5.81 12 9.53 10
Amortization Expense		 - - 0.00 -1.68 -2.59 -1.19 4.89 -4.71 -16 -33 -16
Non-Cash Adjustments To Reconcile Net Income		 4.55 7.66 24 35 41 51 57 115 111 174 306
Changes in Operating Assets and Liabilities, net		 37 12 0.49 -30 -8.44 85 8.46 -26 4.50 43 -25
Net Cash From Investing Activities		 16 -52 -66 5.13 -75 -197 -148 -262 239 -553 17
Net Cash From Continuing Investing Activities		 16 -52 -66 5.13 -75 -197 -148 -262 239 -553 17
Purchase of Property, Plant & Equipment		 -0.56 -1.60 -2.88 -0.89 -2.62 -11 -49 -11 -1.42 -3.91 -25
Purchase of Investments		 -116 -145 -240 -240 -278 -436 -525 -855 -635 -1,293 -1,068
Sale and/or Maturity of Investments		 132 95 177 246 206 250 426 605 876 744 1,110
Net Cash From Financing Activities		 24 17 226 13 160 234 320 516 221 931 524
Net Cash From Continuing Financing Activities		 24 17 226 13 160 234 320 516 221 931 524
Repayment of Debt		 - - - 0.00 134 0.00 0.00 -191 -0.86 -9.62 -414
Issuance of Debt		 15 17 16 9.90 1.71 0.00 0.00 673 50 200 904
Issuance of Common Equity		 8.67 0.00 120 3.23 38 234 324 18 183 760 36
Other Financing Activities, net		 0.00 0.00 91 0.00 -13 -0.10 -4.45 17 -11 -20 -2.47
Other Net Changes in Cash		 - - - - - - - 0.00 -0.02 0.21 -0.72
Cash Interest Paid		 0.09 1.90 2.13 2.88 4.06 9.62 9.18 15 10 26 23

Quarterly Cash Flow Statements for Cytokinetics

This table details how cash moves in and out of Cytokinetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 31 13 6.95 70 -143 48 -21 2.50 152 -103 7.32
Net Cash From Operating Activities		 -96 -74 -130 -99 -102 -66 -132 -128 -108 -143 -145
Net Cash From Continuing Operating Activities		 -96 -74 -130 -99 -102 -66 -132 -128 -108 -143 -145
Net Income / (Loss) Continuing Operations		 -129 -137 -136 -143 -161 -150 -161 -134 -306 -183 -206
Consolidated Net Income / (Loss)		 -129 -137 -136 -143 -161 -150 -161 -134 -306 -183 -206
Depreciation Expense		 1.85 6.34 2.33 2.41 2.41 2.38 2.30 2.29 2.68 2.86 3.38
Amortization Expense		 -3.74 -5.10 -5.22 -8.50 -11 -7.70 -6.17 -4.03 -2.70 -3.08 -1.87
Non-Cash Adjustments To Reconcile Net Income		 34 15 35 37 61 41 39 57 174 38 58
Changes in Operating Assets and Liabilities, net		 1.29 46 -26 13 6.48 49 -5.20 -49 25 2.38 0.82
Net Cash From Investing Activities		 73 -81 33 -652 -45 111 106 53 -71 -71 145
Net Cash From Continuing Investing Activities		 73 -81 33 -652 -45 111 106 53 -71 -71 145
Purchase of Property, Plant & Equipment		 -0.22 -0.08 0.00 -1.92 -0.70 -1.29 -5.66 -4.15 -9.35 -5.64 -5.93
Purchase of Investments		 -118 -226 -143 -815 -214 -121 -164 -223 -335 -346 -107
Sale and/or Maturity of Investments		 191 145 175 166 170 233 276 280 274 280 258
Net Cash From Financing Activities		 54 169 104 821 3.43 2.38 4.75 79 330 111 7.77
Net Cash From Continuing Financing Activities		 54 169 104 821 3.43 2.38 4.75 79 330 111 7.77
Repayment of Debt		 -0.22 -0.22 -0.93 -2.88 -2.89 -2.91 -2.88 -2.70 -405 -2.72 -2.74
Issuance of Debt		 50 - - - - - 0.00 - 729 100 0.00
Issuance of Common Equity		 4.44 169 123 624 6.32 6.48 7.65 6.75 6.94 15 11
Other Financing Activities, net		 - - -18 - - -1.18 -0.01 -0.51 -0.72 -1.22 -0.84
Other Net Changes in Cash		 - -0.02 0.03 - -0.13 0.29 -0.27 -0.68 0.05 0.19 -0.48
Cash Interest Paid		 0.03 0.32 10 0.67 14 0.64 9.65 0.61 9.62 3.04 1.59

Annual Balance Sheets for Cytokinetics

This table presents Cytokinetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 115 170 295 211 290 534 841 1,015 824 1,402 1,425
Total Current Assets		 113 159 274 208 234 474 536 795 628 1,108 917
Cash & Equivalents		 65 67 125 42 36 83 113 66 113 95 123
Short-Term Investments		 46 89 144 156 189 381 359 717 502 981 760
Accounts Receivable		 0.01 0.02 1.11 2.23 5.16 4.42 52 0.15 1.28 17 18
Inventories, net		 - - - - - - - - - - 0.00
Prepaid Expenses		 1.65 2.36 4.29 2.16 3.48 5.74 12 12 12 15 17
Plant, Property, & Equipment, net		 1.75 3.64 3.57 3.20 4.53 13 73 80 69 66 79
Total Noncurrent Assets		 0.38 7.87 17 0.30 52 46 232 139 128 228 428
Long-Term Investments		 0.18 7.67 17 0.00 43 37 152 47 41 145 335
Other Noncurrent Operating Assets		 0.20 0.20 0.43 0.30 8.88 9.28 80 92 87 83 93
Total Liabilities & Shareholders' Equity		 115 170 295 211 290 534 841 1,015 824 1,402 1,425
Total Liabilities		 47 76 185 185 301 420 597 1,123 1,211 1,537 2,084
Total Current Liabilities		 32 33 32 22 26 31 72 85 103 180 202
Short-Term Debt		 0.00 2.50 0.00 2.61 - 2.79 - 0.96 10 12 41
Accounts Payable		 2.24 4.24 5.25 3.76 8.16 8.05 21 26 22 20 22
Accrued Expenses		 8.42 18 17 16 12 19 34 44 43 55 83
Current Deferred Revenue		 21 8.06 9.57 - - - - - 0.00 52 1.61
Other Current Liabilities		 0.13 0.42 0.23 0.07 5.74 1.05 16 14 28 40 54
Total Noncurrent Liabilities		 15 43 153 163 275 389 526 1,038 1,108 1,357 1,882
Long-Term Debt		 15 27 32 40 129 136 143 610 607 646 1,116
Other Noncurrent Operating Liabilities		 - 0.14 106 123 145 166 296 428 501 712 766
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 69 94 110 26 -11 113 244 -108 -386 -135 -660
Total Preferred & Common Equity		 69 94 110 26 -11 113 244 -108 -386 -135 -660
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 69 94 110 26 -11 113 244 -108 -386 -135 -660
Common Stock		 603 613 756 769 853 1,106 1,452 1,482 1,726 2,564 2,826
Retained Earnings		 -535 -518 -646 -743 -865 -992 -1,208 -1,586 -2,112 -2,702 -3,487
Accumulated Other Comprehensive Income / (Loss)		 0.15 0.14 0.34 0.50 0.68 0.15 -0.87 -3.59 -0.01 2.40 0.63

Quarterly Balance Sheets for Cytokinetics

This table presents Cytokinetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 1,076 890 780 741 808 1,524 1,436 1,264 1,226 1,437 1,273
Total Current Assets		 884 681 587 561 639 1,068 1,019 956 887 977 839
Cash & Equivalents		 106 102 69 100 120 190 47 74 75 225 130
Short-Term Investments		 761 562 497 440 499 867 965 865 783 737 689
Accounts Receivable		 2.29 1.01 0.99 2.50 0.83 0.00 0.24 2.01 8.41 1.81 6.83
Inventories, net		 - - - - - - - - - - 0.15
Prepaid Expenses		 14 16 20 20 19 11 6.67 16 20 13 14
Plant, Property, & Equipment, net		 80 79 77 76 68 66 64 67 70 76 82
Total Noncurrent Assets		 111 130 116 104 101 390 353 241 269 383 352
Long-Term Investments		 29 40 27 15 15 305 269 151 178 289 255
Other Noncurrent Operating Assets		 83 90 89 88 86 85 84 90 91 94 97
Total Liabilities & Shareholders' Equity		 1,076 890 780 741 808 1,524 1,436 1,264 1,226 1,437 1,273
Total Liabilities		 1,092 1,119 1,113 1,179 1,204 1,415 1,450 1,530 1,594 1,958 2,100
Total Current Liabilities		 76 75 66 78 89 103 110 160 131 142 199
Short-Term Debt		 - - - - 12 12 12 13 14 17 45
Accounts Payable		 14 17 13 14 13 9.47 12 14 16 22 25
Accrued Expenses		 40 36 31 33 40 40 50 43 52 62 69
Current Deferred Revenue		 - - - - - - - 52 1.34 1.61 1.65
Other Current Liabilities		 22 22 22 31 24 42 37 37 47 40 59
Total Noncurrent Liabilities		 1,015 1,044 1,047 1,102 1,115 1,312 1,340 1,371 1,463 1,816 1,901
Long-Term Debt		 609 611 610 609 607 643 644 645 713 1,048 1,118
Other Noncurrent Operating Liabilities		 407 433 438 493 509 669 696 726 750 767 783
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -16 -229 -333 -439 -396 109 -14 -266 -369 -521 -827
Total Preferred & Common Equity		 -16 -229 -333 -439 -396 109 -14 -266 -369 -521 -827
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -16 -229 -333 -439 -396 109 -14 -266 -369 -521 -827
Common Stock		 1,438 1,490 1,514 1,537 1,852 2,501 2,532 2,595 2,629 2,783 2,868
Retained Earnings		 -1,449 -1,717 -1,846 -1,975 -2,248 -2,391 -2,552 -2,863 -2,998 -3,304 -3,693
Accumulated Other Comprehensive Income / (Loss)		 -5.56 -1.65 -1.46 -0.87 -0.54 -1.02 5.39 1.55 -0.16 0.03 -1.61

Annual Metrics And Ratios for Cytokinetics

This table displays calculated financial ratios and metrics derived from Cytokinetics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -38.95% 271.30% -87.44% 135.64% -14.71% 107.79% 26.15% 34.30% -92.04% 145.34% 376.56%
EBITDA Growth		 -158.86% 154.28% -647.33% 21.92% -12.49% 2.43% -92.00% -94.28% -43.68% -15.50% -6.33%
EBIT Growth		 -154.22% 151.44% -678.53% 23.67% -11.55% 0.41% -98.33% -87.39% -42.12% -11.76% -9.69%
NOPAT Growth		 -153.54% 171.37% -524.77% 21.59% -11.19% 4.98% -98.33% -74.01% -53.05% -8.07% -14.17%
Net Income Growth		 -156.05% 143.87% -876.70% 16.83% -14.49% -4.60% -69.15% -80.65% -35.30% -12.03% -33.15%
EPS Growth		 -136.59% 140.21% -764.10% 24.71% -8.21% 6.64% -42.13% -54.64% -25.87% 3.49% -24.33%
Operating Cash Flow Growth		 110.89% 657.36% -375.16% 0.53% 10.18% 109.84% -1,693.67% -110.15% -38.33% 4.45% -28.83%
Free Cash Flow Firm Growth		 124.57% 171.43% -17.48% -405.85% 33.71% 166.78% -524.37% 3.38% -81.86% 59.84% -307.04%
Invested Capital Growth		 -421.32% -39.75% -262.38% 9.32% -14.62% -66.41% 4.71% -37.82% -29.89% -64.85% -2.92%
Revenue Q/Q Growth		 -29.52% 28.16% -71.27% 42.50% -13.42% 2.78% 226.81% -36.19% -3.65% 473.90% 0.66%
EBITDA Q/Q Growth		 -90.32% 565.95% -60.94% 17.51% -1.95% -22.15% 8.77% -63.38% 0.68% -3.46% -2.78%
EBIT Q/Q Growth		 -87.77% 725.83% -60.15% 18.67% -2.14% -22.43% 7.31% -59.52% -0.08% -2.35% -3.70%
NOPAT Q/Q Growth		 -87.36% 844.26% -63.91% 14.49% -2.33% -15.63% 7.31% -48.12% -0.08% -2.22% -6.86%
Net Income Q/Q Growth		 -89.12% 24,456.72% -59.44% 11.65% -3.55% -11.66% 5.84% -37.86% 0.09% -2.28% -4.39%
EPS Q/Q Growth		 -90.20% 657.14% -61.88% 12.95% -1.44% -3.68% 8.20% -38.34% 2.68% 2.23% -3.97%
Operating Cash Flow Q/Q Growth		 -27.07% 172.82% -72,269.50% 10.40% -7.99% 114.36% -212.31% -21.72% 5.51% 2.09% -17.80%
Free Cash Flow Firm Q/Q Growth		 40.85% 152.75% -77.62% 13.31% -17.11% 210.09% -384.11% -6.86% 6.20% 11.24% -22.62%
Invested Capital Q/Q Growth		 7.47% -241.10% -9.92% -12.08% -5.88% -48.39% 15.04% -7.56% -10.34% -9.48% -1.81%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -127.87% 18.69% -814.44% -269.85% -355.91% -167.13% -254.36% -367.95% -6,640.74% -3,126.19% -697.54%
Operating Margin		 -130.53% 17.56% -848.26% -282.26% -367.97% -168.27% -264.54% -342.75% -6,589.71% -2,902.72% -695.44%
EBIT Margin		 -129.92% 18.00% -828.80% -268.46% -351.09% -168.27% -264.54% -369.12% -6,589.71% -3,001.78% -690.90%
Profit (Net Income) Margin		 -130.86% 15.46% -955.94% -337.41% -452.93% -228.00% -305.72% -411.21% -6,988.63% -3,191.11% -891.60%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.15% 100.00% 95.98% 99.85% 97.17% 95.01% 91.96% 94.19%
Interest Burden Percent		 100.72% 85.91% 115.34% 125.50% 129.00% 141.17% 115.74% 114.65% 111.62% 115.60% 137.01%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -46.69% 20.19% -125.16% -156.57% -1,622.88% -248.50% -120.54% -572.15% 212.96% 226.00% 197.47%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -30.00% 13.42% -47.66% -33.43% -37.66% -22.81% -27.10% -37.62% -53.96% -49.82% -43.04%
Return on Assets (ROA)		 -30.22% 11.53% -54.97% -42.01% -48.58% -30.91% -31.32% -41.91% -57.23% -52.97% -55.55%
Return on Common Equity (ROCE)		 -46.69% 20.19% -125.16% -156.57% -1,622.88% -248.50% -120.54% -572.15% 212.96% 226.00% 197.47%
Return on Equity Simple (ROE_SIMPLE)		 -54.67% 17.44% -116.34% -409.84% 1,112.66% -112.27% -88.29% 360.48% 136.22% 435.49% 0.00%
Net Operating Profit after Tax (NOPAT)		 -26 19 -79 -62 -69 -66 -130 -227 -347 -375 -429
NOPAT Margin		 -91.37% 17.56% -593.79% -197.58% -257.58% -117.79% -185.18% -239.93% -4,612.80% -2,031.90% -486.81%
Net Nonoperating Expense Percent (NNEP)		 -12.56% -1.93% -24.98% -21.49% -35.60% -24.58% -20.14% -46.32% -139.43% -71.16% -114.21%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -45.15% -150.28% -71.95% -86.14%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 68.63% 26.15% 272.80% 99.30% 147.42% 94.61% 137.45% 188.16% 2,305.60% 1,165.50% 322.89%
R&D to Revenue		 161.90% 56.29% 675.46% 282.96% 320.55% 173.66% 227.09% 254.59% 4,384.10% 1,837.22% 472.55%
Operating Expenses to Revenue		 230.53% 82.44% 948.26% 382.26% 467.97% 268.27% 364.54% 442.75% 6,689.71% 3,002.72% 795.44%
Earnings before Interest and Taxes (EBIT)		 -37 19 -111 -85 -94 -94 -186 -349 -496 -555 -608
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -37 20 -109 -85 -96 -93 -179 -348 -500 -578 -614
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.92 5.22 4.00 13.33 0.00 12.97 15.68 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 5.92 5.22 4.00 13.33 0.00 12.97 15.68 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 14.18 4.63 32.85 10.98 23.33 26.35 54.29 45.84 1,087.18 300.50 88.24
Price to Earnings (P/E)		 0.00 29.92 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 3.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 10.79 3.37 13.88 6.01 18.18 19.86 47.46 43.53 1,082.15 269.97 87.56
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 18.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 18.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 19.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 63.35 9.69 0.00 0.00 0.00 123.98 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 28.01 11.95 7.50 0.00 0.00 33.10 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.21 0.32 0.29 1.64 -11.82 1.23 0.59 -5.66 -1.60 -4.85 -1.75
Long-Term Debt to Equity		 0.21 0.29 0.29 1.53 -11.82 1.20 0.59 -5.65 -1.57 -4.77 -1.69
Financial Leverage		 -1.12 -1.42 -1.90 -3.02 -19.66 -4.89 -2.36 -5.15 0.52 1.15 0.79
Leverage Ratio		 1.55 1.75 2.28 3.73 33.41 8.04 3.85 13.65 -3.72 -4.27 -3.56
Compound Leverage Factor		 1.56 1.50 2.63 4.68 43.10 11.35 4.46 15.65 -4.15 -4.93 -4.87
Debt to Total Capital		 17.59% 24.05% 22.44% 62.06% 109.24% 55.06% 36.94% 121.47% 267.15% 125.95% 232.58%
Short-Term Debt to Total Capital		 0.00% 2.01% 0.00% 3.81% 0.00% 1.10% 0.00% 0.19% 4.36% 2.21% 8.28%
Long-Term Debt to Total Capital		 17.59% 22.04% 22.44% 58.24% 109.24% 53.96% 36.94% 121.27% 262.78% 123.74% 224.30%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 82.41% 75.95% 77.56% 37.94% -9.24% 44.94% 63.06% -21.47% -167.15% -25.95% -132.58%
Debt to EBITDA		 -0.40 1.50 -0.29 -0.50 -1.35 -1.49 -0.80 -1.75 -1.23 -1.14 -1.88
Net Debt to EBITDA		 2.65 -6.74 2.33 1.84 1.45 3.88 2.68 0.63 0.08 0.98 0.10
Long-Term Debt to EBITDA		 -0.40 1.38 -0.29 -0.47 -1.35 -1.46 -0.80 -1.75 -1.21 -1.12 -1.82
Debt to NOPAT		 -0.56 1.60 -0.40 -0.68 -1.87 -2.11 -1.10 -2.69 -1.78 -1.75 -2.70
Net Debt to NOPAT		 3.70 -7.17 3.20 2.51 2.00 5.51 3.69 0.96 0.11 1.50 0.14
Long-Term Debt to NOPAT		 -0.56 1.47 -0.40 -0.64 -1.87 -2.07 -1.10 -2.69 -1.75 -1.72 -2.60
Altman Z-Score		 -1.24 1.51 -1.85 -3.93 -3.05 0.02 1.84 -0.07 -0.74 -1.03 -1.94
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.57 4.77 8.45 9.36 8.98 15.20 7.45 9.40 6.12 6.17 4.53
Quick Ratio		 3.52 4.70 8.32 9.05 8.85 15.02 7.28 9.25 6.00 6.08 4.45
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 11 30 25 -76 -50 33 -142 -137 -250 -100 -408
Operating Cash Flow to CapEx		 870.41% 2,366.09% -3,536.98% -11,567.43% -3,471.06% 80.92% -291.62% -2,642.40% -29,260.81% -10,135.43% -2,055.91%
Free Cash Flow to Firm to Interest Expense		 41.21 11.11 1.46 -3.51 -1.83 0.87 -4.85 -2.68 -4.33 -1.16 -1.81
Operating Cash Flow to Interest Expense		 18.22 13.71 -5.99 -4.69 -3.32 0.23 -4.86 -5.86 -7.18 -4.58 -2.27
Operating Cash Flow Less CapEx to Interest Expense		 16.13 13.13 -6.16 -4.73 -3.42 -0.05 -6.53 -6.08 -7.21 -4.62 -2.38
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.23 0.75 0.06 0.12 0.11 0.14 0.10 0.10 0.01 0.02 0.06
Accounts Receivable Turnover		 1.23 5,911.50 23.54 18.85 7.27 11.65 2.50 3.64 10.53 2.06 5.12
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 16.92 39.50 3.71 9.30 6.95 6.25 1.63 1.23 0.10 0.27 1.21
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 297.13 0.06 15.51 19.37 50.22 31.33 145.73 100.26 34.66 177.16 71.34
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 297.13 0.06 15.51 19.37 50.22 31.33 145.73 100.26 34.66 177.16 71.34
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -28 -40 -144 -130 -149 -249 -237 -327 -424 -699 -720
Invested Capital Turnover		 -2.93 -3.13 -0.15 -0.23 -0.19 -0.28 -0.29 -0.34 -0.02 -0.03 -0.12
Increase / (Decrease) in Invested Capital		 -37 -11 -104 13 -19 -99 12 -90 -98 -275 -20
Enterprise Value (EV)		 309 358 186 189 488 1,109 3,343 4,117 8,149 4,987 7,709
Market Capitalization		 406 492 439 346 627 1,471 3,823 4,336 8,186 5,551 7,769
Book Value per Share		 $1.77 $2.33 $2.04 $0.47 ($0.19) $1.60 $2.91 ($1.14) ($3.94) ($1.15) ($5.40)
Tangible Book Value per Share		 $1.77 $2.33 $2.04 $0.47 ($0.19) $1.60 $2.91 ($1.14) ($3.94) ($1.15) ($5.40)
Total Capital		 83 124 142 68 118 252 387 503 231 522 498
Total Debt		 15 30 32 42 129 139 143 611 617 657 1,157
Total Long-Term Debt		 15 27 32 40 129 136 143 610 607 646 1,116
Net Debt		 -97 -134 -254 -156 -139 -362 -481 -219 -38 -564 -60
Capital Expenditures (CapEx)		 0.56 1.56 2.88 0.88 2.62 11 49 11 1.42 3.91 25
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -30 -28 -27 -11 -17 -18 -7.83 -71 -79 -136 -127
Debt-free Net Working Capital (DFNWC)		 81 128 242 188 208 446 464 712 535 940 756
Net Working Capital (NWC)		 81 125 242 185 208 443 464 711 525 928 715
Net Nonoperating Expense (NNE)		 11 2.23 48 44 52 62 85 162 179 214 356
Net Nonoperating Obligations (NNO)		 -97 -134 -254 -156 -139 -362 -481 -219 -38 -564 -60
Total Depreciation and Amortization (D&A)		 0.59 0.74 1.92 -0.44 -1.29 0.64 7.17 1.10 -3.84 -23 -5.85
Debt-free, Cash-free Net Working Capital to Revenue		 -104.63% -26.67% -202.27% -33.79% -64.70% -32.70% -11.11% -75.12% -1,054.06% -737.40% -143.71%
Debt-free Net Working Capital to Revenue		 284.24% 120.18% 1,809.18% 597.08% 773.15% 798.54% 658.56% 752.24% 7,110.93% 5,087.07% 858.37%
Net Working Capital to Revenue		 284.24% 117.83% 1,809.18% 588.81% 773.15% 793.55% 658.56% 751.23% 6,977.07% 5,024.72% 811.60%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.97) $0.41 ($2.59) ($1.95) ($2.11) ($1.97) ($2.80) ($4.33) ($5.45) ($5.26) ($6.54)
Adjusted Weighted Average Basic Shares Outstanding		 39.59M 39.94M 49.40M 54.89M 59.45M 71.11M 84.86M 89.83M 96.52M 111.98M 120.10M
Adjusted Diluted Earnings per Share		 ($0.97) $0.39 ($2.59) ($1.95) ($2.11) ($1.97) ($2.80) ($4.33) ($5.45) ($5.26) ($6.54)
Adjusted Weighted Average Diluted Shares Outstanding		 39.59M 42.56M 49.40M 54.89M 59.45M 71.11M 84.86M 89.83M 96.52M 111.98M 120.10M
Adjusted Basic & Diluted Earnings per Share		 ($0.97) $0.00 $0.00 ($1.95) ($2.11) ($1.97) ($2.80) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 38.81M 41.73M 54.01M 54.42M 57.58M 64.52M 76.89M 95.16M 103.00M 118.41M 123.16M
Normalized Net Operating Profit after Tax (NOPAT)		 -26 13 -79 -62 -69 -66 -130 -227 -347 -375 -429
Normalized NOPAT Margin		 -91.37% 12.29% -593.79% -197.58% -257.58% -117.79% -185.18% -239.93% -4,612.80% -2,031.90% -486.81%
Pre Tax Income Margin		 -130.86% 15.46% -955.94% -336.92% -452.93% -237.55% -306.19% -423.20% -7,355.55% -3,470.07% -946.60%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -138.93 7.10 -6.52 -3.92 -3.45 -2.43 -6.35 -6.83 -8.60 -6.41 -2.70
NOPAT to Interest Expense		 -97.70 6.93 -4.67 -2.89 -2.53 -1.70 -4.45 -4.44 -6.02 -4.34 -1.90
EBIT Less CapEx to Interest Expense		 -141.02 6.52 -6.69 -3.96 -3.54 -2.71 -8.02 -7.05 -8.63 -6.46 -2.81
NOPAT Less CapEx to Interest Expense		 -99.80 6.35 -4.84 -2.93 -2.63 -1.99 -6.11 -4.66 -6.05 -4.38 -2.01
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Cytokinetics

This table displays calculated financial ratios and metrics derived from Cytokinetics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 123,162,807.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 123,162,807.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -1.67
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -84.97% -14.56% -81.90% -71.28% 22.49% 912.38% 89.10% 0.00% 318.14% 3.37% 1,125.78%
EBITDA Growth		 7.76% -7.88% -2.76% -6.85% -39.79% -13.81% -20.81% 8.64% -2.98% -11.25% -16.80%
EBIT Growth		 8.79% -11.03% -1.42% -3.43% -34.55% -9.05% -20.51% 5.72% -8.73% -15.25% -20.76%
NOPAT Growth		 -12.75% -0.31% -1.42% -6.66% -15.16% -9.12% -23.29% 14.34% -18.43% -28.28% -17.98%
Net Income Growth		 9.06% 0.35% -3.32% -11.41% -24.05% -9.59% -18.97% 6.24% -90.71% -22.00% -27.67%
EPS Growth		 11.18% 9.80% 3.62% 2.24% -0.74% 8.70% -2.26% 14.50% -87.50% -19.84% -22.79%
Operating Cash Flow Growth		 -14.48% 24.60% -5.91% 18.47% -5.50% 11.44% -1.63% -29.12% -5.92% -117.56% -10.52%
Free Cash Flow Firm Growth		 90.72% 1,102.05% 100.89% 431.65% 3,376.93% 2,009.66% 14,135.80% -99.52% -131.19% -158.76% -150.27%
Invested Capital Growth		 -26.62% -29.89% -27.76% -89.48% -66.13% -64.85% -69.07% -13.19% -10.67% -2.92% -5.75%
Revenue Q/Q Growth		 -56.40% 342.33% -50.06% -70.18% 85.94% 3,555.94% -90.67% 4,128.56% -97.10% 817.10% 9.01%
EBITDA Q/Q Growth		 -0.03% -19.18% 7.64% 2.96% -30.86% 2.97% 1.95% 19.97% -35.26% 2.66% -10.85%
EBIT Q/Q Growth		 -0.14% -22.19% 10.49% 5.56% -30.27% 0.97% 1.08% 19.08% -37.16% 2.78% -11.91%
NOPAT Q/Q Growth		 -0.18% -4.21% 0.93% -3.12% -8.17% 1.25% -11.93% 28.35% -49.55% -6.96% -2.94%
Net Income Q/Q Growth		 -0.61% -5.77% 0.92% -5.66% -12.02% 6.56% -7.57% 16.73% -127.86% 40.22% -12.57%
EPS Q/Q Growth		 -0.75% -2.22% 3.62% 1.50% -3.82% 7.35% -7.94% 17.65% -127.68% 40.78% -10.60%
Operating Cash Flow Q/Q Growth		 21.02% 23.04% -74.92% 23.31% -2.20% 35.40% -100.73% 2.57% 16.17% -32.69% -1.97%
Free Cash Flow Firm Q/Q Growth		 91.77% 277.34% -85.34% 15,406.81% -18.73% 14.17% -1.06% -99.48% -5,367.68% -115.10% 15.35%
Invested Capital Q/Q Growth		 -21.70% -10.34% 2.80% -45.17% -6.70% -9.48% 0.31% 2.81% -4.33% -1.81% -2.44%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 86.81%
EBITDA Margin		 -31,033.86% -8,361.36% -15,464.43% -50,326.10% -35,417.06% -939.98% -9,879.99% -186.99% -8,722.73% -925.82% -941.43%
Operating Margin		 -32,345.24% -7,620.69% -15,117.96% -52,277.91% -30,410.58% -821.41% -9,856.30% -167.00% -8,613.38% -1,004.60% -948.69%
EBIT Margin		 -30,535.98% -8,435.17% -15,117.96% -47,879.12% -33,542.33% -908.57% -9,634.64% -184.38% -8,721.85% -924.62% -949.20%
Profit (Net Income) Margin		 -34,238.62% -8,187.56% -16,244.67% -57,557.43% -34,674.95% -886.28% -10,220.14% -201.25% -15,814.98% -1,030.87% -1,064.48%
Tax Burden Percent		 100.00% 86.59% 94.49% 99.86% 90.40% 85.05% 92.17% 91.18% 96.76% 94.10% 94.92%
Interest Burden Percent		 112.13% 112.10% 113.72% 120.38% 114.36% 114.69% 115.08% 119.71% 187.40% 118.48% 118.14%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 231.64% 212.96% 169.74% 485.63% 254.64% 226.00% 185.72% 466.09% 281.08% 197.47% 151.81%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -262.73% -69.07% -66.82% -130.27% -99.21% -15.08% -178.71% -11.53% -531.09% -57.61% -79.16%
Return on Assets (ROA)		 -294.59% -67.05% -71.79% -156.61% -102.56% -14.71% -189.57% -12.59% -963.01% -64.23% -88.78%
Return on Common Equity (ROCE)		 231.64% 212.96% 169.74% 485.63% 254.64% 226.00% 185.72% 466.09% 281.08% 197.47% 151.81%
Return on Equity Simple (ROE_SIMPLE)		 120.04% 0.00% 133.94% -502.33% 4,143.50% 0.00% 230.94% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -86 -89 -88 -91 -99 -97 -109 -78 -117 -125 -129
NOPAT Margin		 -22,641.67% -5,334.49% -10,582.57% -36,594.54% -21,287.41% -574.99% -6,899.41% -116.90% -6,029.36% -703.22% -664.08%
Net Nonoperating Expense Percent (NNEP)		 -37.57% -37.18% -86.00% -15.13% -21.73% -17.51% -23.46% -11.09% -46.74% -18.64% -45.38%
Return On Investment Capital (ROIC_SIMPLE)		 - -38.59% - - - -18.65% -27.81% -21.76% -21.44% -25.09% -38.26%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 13.19%
SG&A Expenses to Revenue		 10,611.38% 2,638.40% 5,449.10% 20,411.25% 12,235.85% 368.28% 3,633.25% 98.43% 3,587.71% 516.60% 541.96%
R&D to Revenue		 21,833.86% 5,082.30% 9,768.86% 31,966.67% 18,274.73% 553.13% 6,323.05% 168.57% 5,125.67% 587.99% 493.54%
Operating Expenses to Revenue		 32,445.24% 7,720.69% 15,217.96% 52,377.91% 30,510.58% 921.41% 9,956.30% 267.00% 8,713.38% 1,104.60% 1,035.50%
Earnings before Interest and Taxes (EBIT)		 -115 -141 -126 -119 -155 -154 -152 -123 -169 -164 -184
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -117 -140 -129 -125 -164 -159 -156 -125 -169 -164 -182
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 52.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 52.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 361.88 1,087.18 1,832.23 1,812.69 1,929.92 300.50 247.63 45.89 75.19 88.24 76.72
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 368.83 1,082.15 1,827.91 1,587.05 1,735.81 269.97 225.21 42.30 73.07 87.56 77.56
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -1.39 -1.60 -1.56 6.03 -47.16 -4.85 -2.47 -1.97 -2.04 -1.75 -1.41
Long-Term Debt to Equity		 -1.39 -1.57 -1.53 5.93 -46.33 -4.77 -2.42 -1.93 -2.01 -1.69 -1.35
Financial Leverage		 0.51 0.52 0.18 3.07 1.26 1.15 0.67 3.91 1.52 0.79 0.31
Leverage Ratio		 -3.99 -3.72 -2.72 -10.26 -4.81 -4.27 -3.13 -10.57 -5.37 -3.56 -2.32
Compound Leverage Factor		 -4.48 -4.17 -3.09 -12.35 -5.50 -4.89 -3.60 -12.65 -10.06 -4.21 -2.74
Debt to Total Capital		 357.79% 267.15% 278.47% 85.78% 102.17% 125.95% 168.01% 202.79% 195.72% 232.58% 346.03%
Short-Term Debt to Total Capital		 0.00% 4.36% 5.19% 1.51% 1.79% 2.21% 3.31% 4.01% 3.17% 8.28% 13.34%
Long-Term Debt to Total Capital		 357.79% 262.78% 273.28% 84.27% 100.37% 123.74% 164.70% 198.77% 192.55% 224.30% 332.69%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -257.79% -167.15% -178.47% 14.22% -2.17% -25.95% -68.01% -102.79% -95.72% -132.58% -246.03%
Debt to EBITDA		 -1.21 -1.23 -1.23 -1.28 -1.18 -1.14 -1.09 -1.23 -1.78 -1.88 -1.82
Net Debt to EBITDA		 -0.11 0.08 0.03 1.38 1.12 0.98 0.71 0.52 0.31 0.10 -0.14
Long-Term Debt to EBITDA		 -1.21 -1.21 -1.20 -1.26 -1.15 -1.12 -1.07 -1.20 -1.75 -1.82 -1.75
Debt to NOPAT		 -1.75 -1.78 -1.77 -1.85 -1.79 -1.75 -1.66 -1.90 -2.66 -2.70 -2.59
Net Debt to NOPAT		 -0.16 0.11 0.05 2.00 1.70 1.50 1.09 0.81 0.46 0.14 -0.20
Long-Term Debt to NOPAT		 -1.75 -1.75 -1.74 -1.82 -1.76 -1.72 -1.63 -1.86 -2.61 -2.60 -2.49
Altman Z-Score		 -2.02 0.68 -0.16 0.72 0.49 -0.09 -0.93 -1.46 -0.83 -0.91 -1.53
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 7.22 6.12 7.19 10.39 9.28 6.17 5.99 6.76 6.88 4.53 4.21
Quick Ratio		 6.97 6.00 6.98 10.28 9.22 6.08 5.89 6.61 6.78 4.45 4.14
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -4.75 8.43 1.24 192 156 178 176 0.92 -49 -104 -88
Operating Cash Flow to CapEx		 -43,729.55% -96,151.95% 0.00% -5,186.06% -14,479.32% -5,082.95% -2,323.75% -3,093.75% -1,149.29% -2,527.48% -2,452.90%
Free Cash Flow to Firm to Interest Expense		 -0.34 0.49 0.07 7.88 6.98 7.87 7.67 0.04 -0.33 -3.44 -2.65
Operating Cash Flow to Interest Expense		 -6.87 -4.34 -7.48 -4.09 -4.55 -2.90 -5.74 -5.28 -0.73 -4.70 -4.36
Operating Cash Flow Less CapEx to Interest Expense		 -6.89 -4.34 -7.48 -4.17 -4.58 -2.96 -5.98 -5.46 -0.79 -4.89 -4.54
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.01 0.00 0.00 0.00 0.02 0.02 0.06 0.06 0.06 0.08
Accounts Receivable Turnover		 3.26 10.53 4.08 0.00 2.35 2.06 13.51 0.00 85.24 5.12 23.94
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.10 0.10 0.05 0.04 0.05 0.27 0.28 1.27 1.25 1.21 1.41
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.05
Days Sales Outstanding (DSO)		 111.93 34.66 89.50 0.00 155.51 177.16 27.03 0.00 4.28 71.34 15.24
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 7,249.55
Cash Conversion Cycle (CCC)		 111.93 34.66 89.50 0.00 155.51 177.16 27.03 0.00 4.28 71.34 -7,234.30
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -384 -424 -412 -599 -639 -699 -697 -678 -707 -720 -737
Invested Capital Turnover		 -0.02 -0.02 -0.01 -0.01 -0.01 -0.03 -0.03 -0.13 -0.13 -0.12 -0.15
Increase / (Decrease) in Invested Capital		 -81 -98 -90 -283 -254 -275 -285 -79 -68 -20 -40
Enterprise Value (EV)		 2,882 8,149 6,858 4,974 5,588 4,987 4,328 3,637 6,391 7,709 8,207
Market Capitalization		 2,828 8,186 6,875 5,681 6,212 5,551 4,759 3,946 6,576 7,769 8,118
Book Value per Share		 ($4.57) ($3.94) ($3.89) $1.04 ($0.12) ($1.15) ($2.25) ($3.09) ($4.36) ($5.40) ($6.71)
Tangible Book Value per Share		 ($4.57) ($3.94) ($3.89) $1.04 ($0.12) ($1.15) ($2.25) ($3.09) ($4.36) ($5.40) ($6.71)
Total Capital		 170 231 222 764 642 522 392 359 544 498 336
Total Debt		 609 617 618 655 656 657 658 727 1,066 1,157 1,163
Total Long-Term Debt		 609 607 607 643 644 646 645 713 1,048 1,116 1,118
Net Debt		 54 -38 -16 -707 -625 -564 -431 -309 -186 -60 89
Capital Expenditures (CapEx)		 0.22 0.08 0.00 1.92 0.70 1.29 5.66 4.15 9.35 5.64 5.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -56 -79 -58 -80 -91 -136 -129 -88 -110 -127 -133
Debt-free Net Working Capital (DFNWC)		 484 535 561 977 920 940 809 770 852 756 685
Net Working Capital (NWC)		 484 525 550 965 909 928 796 755 835 715 640
Net Nonoperating Expense (NNE)		 44 48 47 52 62 53 52 56 189 58 77
Net Nonoperating Obligations (NNO)		 54 -38 -16 -707 -625 -564 -431 -309 -186 -60 89
Total Depreciation and Amortization (D&A)		 -1.88 1.23 -2.89 -6.09 -8.68 -5.32 -3.87 -1.75 -0.02 -0.21 1.50
Debt-free, Cash-free Net Working Capital to Revenue		 -710.76% -1,054.06% -1,534.97% -2,559.73% -2,838.86% -737.40% -670.89% -102.64% -125.83% -143.71% -126.13%
Debt-free Net Working Capital to Revenue		 6,189.29% 7,110.93% 14,961.86% 31,159.96% 28,589.90% 5,087.07% 4,211.09% 895.34% 974.71% 858.37% 647.44%
Net Working Capital to Revenue		 6,189.29% 6,977.07% 14,654.82% 30,792.37% 28,232.03% 5,024.72% 4,143.65% 878.60% 954.96% 811.60% 605.09%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.35) ($1.38) ($1.33) ($1.31) ($1.36) ($1.26) ($1.36) ($1.12) ($2.55) ($1.51) ($1.67)
Adjusted Weighted Average Basic Shares Outstanding		 96.07M 96.52M 101.92M 109.24M 117.69M 111.98M 118.50M 119.46M 119.98M 120.10M 123.27M
Adjusted Diluted Earnings per Share		 ($1.35) ($1.38) ($1.33) ($1.31) ($1.36) ($1.26) ($1.36) ($1.12) ($2.55) ($1.51) ($1.67)
Adjusted Weighted Average Diluted Shares Outstanding		 96.07M 96.52M 101.92M 109.24M 117.69M 111.98M 118.50M 119.46M 119.98M 120.10M 123.27M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 98.05M 103.00M 104.85M 117.66M 118.01M 118.41M 119.43M 119.66M 122.26M 123.16M 124.43M
Normalized Net Operating Profit after Tax (NOPAT)		 -86 -89 -88 -91 -99 -97 -109 -78 -117 -125 -129
Normalized NOPAT Margin		 -22,641.67% -5,334.49% -10,582.57% -36,594.54% -21,287.41% -574.99% -6,899.41% -116.90% -6,029.36% -703.22% -664.08%
Pre Tax Income Margin		 -34,238.62% -9,455.74% -17,192.34% -57,637.75% -38,358.32% -1,042.05% -11,087.84% -220.72% -16,344.32% -1,095.47% -1,121.43%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -8.25 -8.27 -7.29 -4.91 -6.96 -6.81 -6.63 -5.07 -1.14 -5.41 -5.51
NOPAT to Interest Expense		 -6.12 -5.23 -5.10 -3.75 -4.42 -4.31 -4.75 -3.22 -0.79 -4.12 -3.86
EBIT Less CapEx to Interest Expense		 -8.26 -8.27 -7.29 -4.99 -7.00 -6.86 -6.88 -5.24 -1.21 -5.60 -5.69
NOPAT Less CapEx to Interest Expense		 -6.13 -5.23 -5.10 -3.83 -4.45 -4.36 -4.99 -3.39 -0.85 -4.30 -4.03
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Below is a concise, investor-focused look at Cytokinetics (CYTK) using the latest four years of quarterly data available in the provided statements. The focus is on trends in revenue, profitability, cash flow, and balance-sheet leverage, highlighting what may matter most to a retail investor weighing growth vs. risk.

  • Significant debt issuance in 2025: In Q3 2025 Cytokinetics issued debt of $729.46 million, contributing to a net cash from continuing financing activities of $330.47 million in that quarter.
  • Strong financing pattern in 2025: Across the four quarters of 2025, net cash from continuing financing activities totaled roughly $1.23 billion (Q2: about $785.33M; Q3: about $330.47M; Q4: about $110.71M; Q1: about $4.75M). This shows repeated access to external funding to support operations and investments.
  • Ongoing equity/debt funding in 2025: In addition to debt, Cytokinetics raised capital via common equity in at least Q1 2025 (Issuance of Common Equity: about $14.65 million) and again in Q3 2025 (Issuance of Common Equity: about $6.94 million). These rounds provide additional liquidity without immediately increasing burn at the operating level.
  • Liquidity improvement signals in 2025 Q3: Cash & equivalents stood at about $225.5 million, with short-term investments around $737.1 million. Total current assets were near $977.3 million and total assets about $1.436 billion, indicating a relatively strong liquidity position versus annual burn rates observed in operating cash flow.
  • Revenue uptick in 2025 Q4: Total revenue for Q4 2025 rose to $17.755 million, up meaningfully from about $1.957 million in Q4 2024, suggesting a potential early sign of revenue growth or milestone-related receipts.
  • Shares outstanding and earnings metrics: The company continues to report losses, but weighted average shares outstanding for recent quarters stay in a similar range (roughly 118–123 million on a basic/diluted basis). This indicates that the per-share negative earnings are largely driven by losses rather than a dilutive equity event in the near term.
  • Leverage trend in 2025: Long-term debt rose from about $713 million (Q2 2025) to around $1.05 billion (Q3 2025). This indicates higher leverage in 2025 as the company leverages financing activity to fund operations and investments, a neutral to cautionary signal depending on the use of raised funds and visibility of near-term cash generation.
  • Net income remains deeply negative: Q1 2025 net income attributable to common shareholders was about -$161.38 million; Q2 2025 about -$134.37 million; Q3 2025 about -$306.18 million; Q4 2025 about -$183.03 million. The pattern of quarterly losses underscores ongoing profitability challenges.
  • Operating cash flow is negative across the year: Net cash from continuing operating activities was approximately -$131.62 million (Q1 2025), -$128.24 million (Q2 2025), -$107.51 million (Q3 2025), and -$142.65 million (Q4 2025). Sustained cash burn from operations is a key consideration for long-term durability without relying on financing activity.
  • Total equity remains negative and growing concern: Total common equity has run negative across recent periods (e.g., roughly -$330 million to -$521 million across 2025 quarters), indicating ongoing accumulation of losses that erode shareholders’ equity and could constrain future financing terms or capital flexibility.
05/22/26 08:09 AM ETAI Generated. May Contain Errors.

Cytokinetics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Cytokinetics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Cytokinetics' net income appears to be on an upward trend, with a most recent value of -$784.96 million in 2025, rising from -$37.50 million in 2015. The previous period was -$589.53 million in 2024. Check out Cytokinetics' forecast to explore projected trends and price targets.

Cytokinetics' total operating income in 2025 was -$612.26 million, based on the following breakdown:
  • Total Gross Profit: $88.04 million
  • Total Operating Expenses: $700.30 million

Over the last 10 years, Cytokinetics' total revenue changed from $28.66 million in 2015 to $88.04 million in 2025, a change of 207.2%.

Cytokinetics' total liabilities were at $2.08 billion at the end of 2025, a 35.6% increase from 2024, and a 4,367.9% increase since 2015.

In the past 10 years, Cytokinetics' cash and equivalents has ranged from $36.43 million in 2019 to $125.21 million in 2017, and is currently $122.52 million as of their latest financial filing in 2025.

Over the last 10 years, Cytokinetics' book value per share changed from 1.77 in 2015 to -5.40 in 2025, a change of -405.6%.


Related Companies

Financial statements for NASDAQ:CYTK last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
System failure: The strongest leverage for gold…
$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...
Golden Portfolio | Sponsoredtc pixel
SMX Could Be One of the Most Interesting Small Caps Right Now
SMX (Security Matters) is developing molecular-level markers that embed digital identities directly into plast...
Smallcaps Daily | Sponsoredtc pixel
New wave of tech IPOs coming?
Cerebras surged 68% on its first trading day, hitting a nearly $67 billion valuation - and investors are now a...
Mode Mobile | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
I had never heard of this 1888 account
An investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...
The Oxford Club | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
How to Profit from Elon’s AI lab before it goes public
Elon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...
InvestorPlace | Sponsoredtc pixel